Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant chemotherapy + SBRT ± durvalumab ± oleclumab in luminal B breast cancer
2024-511849-19-00Phase 2Authorised
- Sponsor
- Institut Jules Bordet
- Start
- Oct 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised trial of durvalumab, oleclumab, doxorubicin, paclitaxel and cyclophosphamide in breast cancer (3 arms), sponsored by Institut Jules Bordet. Primary endpoint: Residual cancer burden (RCB 0–1 vs RCB 2–3) at surgery. Planned start Oct 2024; status: authorised.
02
Drugs
durvalumaboleclumabdoxorubicinpaclitaxelcyclophosphamide
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-511849-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511849-19-00.